NEWARK, Calif., Sept. 9, 2015 /PRNewswire/ -- While an estimated 36 million Americans suffer from migraine[2], only one of every three people speak to a doctor[3] about their headaches. Of those, only half obtain the proper diagnosis[4]. In recognition of Migraine Awareness Week, September 6-12, 2015, Depomed, Inc. (NASDAQ: DEPO) has teamed with the American Migraine Foundation (AMF) to highlight the importance of seeking and consulting with a headache specialist who can help properly diagnose and correctly treat migraine.
"Given the disabling nature of a migraine, it is important for people who experience frequent attacks not to endure the pain in silence but rather to speak with a specialist in order to receive the proper diagnosis and to understand their treatment options," said Srinivas G. Rao, MD, PhD, Senior Vice President and Chief Medical Officer of Depomed. "Depomed is deeply committed both to raising awareness about migraine and to supporting research activities aimed at helping better understand this disease."
For more than 90 percent of those affected, migraine interferes with the activities surrounding everyday life including the ability to maintain business and personal activities.[5] In order to raise awareness of the impact of migraine and to encourage treatment, Depomed and AMF have produced "Demystifying Migraine," a patient-focused animated story that provides a glimpse into the life of a migraine sufferer created to help individuals with the medical condition to take back control of their lives. As part of its ongoing commitment to help migraine sufferers find a treatment that works for them, Depomed will donate $1 to the AMF with every video view and $2 for every Share on Facebook and Twitter, up to $15,000. To view and Share the video, please click here:
https://vimeo.com/user39763326/demystifyingmigraine
Supplementing the information provided in this animation, patients and caregivers are invited to explore AMF's website (www.americanmigrainefoundation.org) which provides essential information on how to find a local headache specialist, how to prepare for your visit, and an overview of potential treatment options. Additionally, the site includes information on migraine and headache resources and support, as well as tips on living with migraine.
About Migraine
Some 36 million Americans live with migraine, more than the number who have asthma and diabetes combined.[6] An estimated seven million Americans live with chronic migraine, a highly disabling neurological disorder. Migraine can be extremely disabling and costly, accounting for more than $20 billion in direct (e.g. doctor visits, medications) and indirect (e.g. missed work, lost productivity) expenses each year in the United States.
About the American Migraine Foundation
The American Migraine Foundation is a non-profit foundation supported by the American Headache Society and generous donors dedicated to the advancement of migraine research. Its mission is to support innovative research that will lead to improvement in the lives of those who suffer from migraine and other disabling headaches. For more information, visit www.americanmigrainefoundation.org. The foundation is the companion website to the American Headache Society (www.americanheadachesociety.org), the professional services organization for the world's foremost clinicians and researchers working in migraine.
About Depomed
Depomed is a specialty pharmaceutical company that commercializes products for pain and neurology related disorders. Our NUCYNTA® franchise includes NUCYNTA® ER (tapentadol) extended release tablets, CII indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment, and NUCYNTA® (tapentadol) oral tablets, CII, an immediate release version of tapentadol, for management of moderate to severe acute pain in adults. Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia. CAMBIA® (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks with or without aura in adults (18 years of age or older). Zipsor® (diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain in adults. Lazanda® (fentanyl) Nasal Spray, CII is an intranasal fentanyl drug used to manage breakthrough cancer pain in adults (18 years of age or older) who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Gralise, Nucynta ER and various partner product candidates are formulated with Depomed's proven, proprietary Acuform® drug delivery technology. Additional information about Depomed may be found at www.depomed.com.
Forward-Looking Statements
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995. The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to, those related to Depomed's prospects as a standalone business, Depomed's business strategy, expectations regarding Depomed's future financial results and the ability to create shareholder value, expectations regarding anticipated growth and the future contributions and potential of NUCYNTA, and other risks detailed in the company's Securities and Exchange Commission filings, including the company's Annual Report on Form 10-K for the year ended December 31, 2014 and its most recent Quarterly Report on Form 10-Q. The inclusion of forward-looking statements should not be regarded as a representation that any of the company's plans, objectives or expectations will be achieved. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
NUCYNTA®, Gralise® CAMBIA®, Zipsor®, Lazanda® and Acuform® are registered trademarks of Depomed, Inc.
Investor Contact:
Depomed, Inc.
Christopher Keenan
510-744-8000
ckeenan@depomed.com
Media Contact:
Mark Corbae
Canale Communications for Depomed
619-849-5375
mark@canalecomm.com
[1]Munakata J, Hazard E, Serrano D, Klingman D, Rupnow MF, Tierce J, Reed M, Lipton RB. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2009 Apr;49(4):498-508.
[2]American Migraine Foundation. About Migraine. 2015. Available: http://www.americanmigrainefoundation.org/about-migraine/. Accessed April 9, 2015.
[3]Munakata J, Hazard E, Serrano D, Klingman D, Rupnow MF, Tierce J, Reed M, Lipton RB. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2009 Apr;49(4):498-508.
[4]National Headache Foundation. Facts About Migraine. Available: http://www.headaches.org/2005/08/12/facts-about-migraine/. Accessed September 9, 2015.
[5]Migraine Research Foundation. Migraine Fact Sheet. 2015. Available:http://www.migraineresearchfoundation.org/fact-sheet.html, Accessed April 9, 2015.
[6]Migraine Research Foundation. "Migraine Fact Sheet" Available: http://www.migraineresearchfoundation.org/fact-sheet.html Accessed May 6, 2015.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/depomed-and-the-american-migraine-foundation-join-forces-to-highlight-need-for-the-proper-diagnosis-management-and-treatment-of-migraine-300139776.html
SOURCE Depomed, Inc.
